"Jan. 21, 2013 -- The number of children with ADHD is rising rapidly, according to a study of more than 840,000 California children.
While the research findings echo those of nationwide studies, the new study is stronger than some other stud"...
DOSAGE AND ADMINISTRATION
General Dosing Information
KAPVAY is an extended-release tablet to be taken orally with or without food. Swallow tablets whole. Do not crush, chew, or break tablets because this will increase the rate of clonidine release.
Due to the lack of controlled clinical trial data and differing pharmacokinetic profiles, substitution of KAPVAY for other clonidine products on a mg-per-mg basis is not recommended [see CLINICAL PHARMACOLOGY].
The dose of KAPVAY, administered either as monotherapy or as adjunctive therapy to a psychostimulant, should be individualized according to the therapeutic needs and response of the patient. Dosing should be initiated with one 0.1 mg tablet at bedtime, and the daily dosage should be adjusted in increments of 0.1 mg/day at weekly intervals until the desired response is achieved. Doses should be taken twice a day, with either an equal or higher split dosage being given at bedtime (see Table 1).
Table 1 : KAPVAY Dosing
|Total Daily Dose||Morning Dose||Bedtime Dose|
|0.1 mg/day||0.1 mg|
|0.2 mg/day||0.1 mg||0.1 mg|
|0.3 mg/day||0.1 mg||0.2 mg|
|0.4 mg/day||0.2 mg||0.2 mg|
Doses of KAPVAY higher than 0.4 mg/day (0.2 mg twice daily) were not evaluated in clinical trials for ADHD and are not recommended.
When KAPVAY is being added-on to a psychostimulant, the dose of the psychostimulant can be adjusted depending on the patient's response to KAPVAY.
If patients miss a dose of KAPVAY, they should skip that dose and take the next dose as scheduled. Do not take more than the prescribed total daily amount of KAPVAY in any 24-hour period.
Dosage Forms And Strengths
KAPVAY tablets are available in two strengths, 0.1 mg and 0.2 mg as an extended-release formulation. Both the 0.1 mg and 0.2 mg tablets are white, non-scored, standard convex with debossing on one side. The 0.1 mg tablets are round and the 0.2 mg tablets are oval. KAPVAY tablets must be swallowed whole and never crushed, cut or chewed.
Storage And Handling
KAPVAY extended-release tablets are white, non-scored, standard convex with debossing (“651” for 0.1 mg and “652” for 0.2 mg) on one side.
NDC 59212-658-60 – 0.1 mg round
tablets supplied in bottles containing 60 tablets.
NDC 59212-659-60 – 0.2 mg oval tablets supplied in bottles containing 60 tablets.
Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].
Dispense in a tight container.
Manufactured for: Concordia Pharmaceuticals Inc. St. Michael, Barbados BB11005. Revised: 2015This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 7/1/2015
Additional Kapvay Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.